Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.
BenowitzNLJacobPIIIAhijevychK. (2002) Biochemical verification of tobacco use and cessation. Nicotine Tob Res4: 149–159.
2.
BogenschutzMPPommyJM (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal4: 543–555.
3.
BowenWTSoskinRAChotlosJW (1970) Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study. J Nerv Ment Dis150: 111–118.
4.
BramerSLKallungalBA (2003) Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers8: 187–203.
5.
CahillKStevensSLancasterT (2014) Pharmacological treatments for smoking cessation. JAMA311: 193–194.
6.
Carhart-HarrisRLErritzoeDWilliamsT. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci109: 2138–2143.
7.
Carhart-HarrisRLLeechRTagliazucchiE. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Human Neurosci8: 1–20.
8.
ChwelosNBlewettDBSmithCM. (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quart J Stud Alcohol20: 577–590.
9.
ColeCCrumRMFordDE (2006) Associations between spirituality and substance abuse symptoms in the Baltimore Epidemiologic Catchment Area follow-up, 1993–1996. J Addict Dis25: 125–132.
10.
DiClementeCCProchaskaJO (1985) Processes and stages of change: Coping and competence in smoking behavior change. In: ShiffmanSWillsTA (eds) Coping and Substance Abuse. New York, NY: Academic Press: 319–343.
11.
DiClementeCCProchaskaJOGibertiniM (1985) Self-efficacy and the stages of self-change of smoking. Cognit Ther Res9: 181–200.
12.
FagerströmK (2012) Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res14: 75–78.
13.
FantegrossiWEWoodsJHWingerG (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol15: 149–157.
14.
FirstMBSpitzerRLGibbonMWilliamsJB (2012) Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet. American Psychiatric Pub.
15.
GalanterM (2006) Spirituality and addiction: A research and clinical perspective. Am J Addict15: 286–292.
16.
GriffithsRRBigelowGEHenningfieldJE (1980) Similarities in animal and human drug-taking behavior. Adv Subst Abuse1: 1–90.
GriffithsRRRichardsWAJohnsonMW. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol22: 621–632.
19.
GriffithsRRRichardsWAMcCannU. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl)187: 268–283.
20.
GonzalesDRennardSINidesM. (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA296: 47–55.
21.
GrinspoonLBakalarJB (1979) Psychedelic drugs reconsidered. New York: Basic Books.
22.
GrobCSDanforthALChopraGS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
23.
HallSMHumfleetGLMuñozRF. (2009) Extended treatment of older cigarette smokers. Addiction104: 1043–1052.
24.
HalpernJH (1996) The use of hallucinogens in the treatment of addiction. Addict Res Theory4: 177–189.
25.
HalpernJHPopeHG (2003) Hallucinogen persisting perception disorder: What do we know after 50 years?Drug Alcohol Depend69: 109–119.
26.
HeathertonTFKozlowskiLTFreckerRC. (1991) The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict86: 1119–1127.
27.
HollisterLESheltonJKriegerG (1969) A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry125: 1352–1357.
28.
HoodRW (1975) The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig14: 29–41.
29.
HoodRWGhorbaniNWatsonPJ. (2001) Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. J Sci Study Relig40: 691–705.
30.
HughesJRKeelyJPNiauraRS. (2003) Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res5: 13–25.
31.
JavorsMAHatchJPLambRJ (2005) Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction100: 159–167.
32.
JohnsonMWRichardsWAGriffithsRR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol22(6): 603–620.
33.
JohnsonMWSewellRAGriffithsRR (2012) Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend123: 132–140.
34.
JorenbyDEHaysJTRigottiNA. (2006) Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA296: 56–63.
35.
Kabat-ZinnJ (1990) Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Delacorte.
KrebsTSJohansenPØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharm26: 994–1002.
38.
LudwigALevineJStarkL. (1969) A clinical study of LSD treatment in alcoholism. Am J Psychiatry126: 59–69.
39.
ManginiM (1998) Treatment of alcoholism using psychedelic drugs: A review of the program of research. J Psychoactive Drugs30: 381–418.
40.
MarksDF (1993) The QUIT FOR LIFE Programme: An easier way to stop smoking and not start again. Leicester, UK: British Psychological Society.
41.
MarksDFSykesCM (2002) Randomized controlled trial of cognitive behavioural therapy for smokers living in a deprived area of London: Outcome at one-year follow-up. Psychol Health Med7: 17–24.
42.
MiddletonETMoriceAH (2000) Breath carbon monoxide as an indication of smoking habit. Chest117: 758–763.
43.
MottilloSFilionKBBélisleP. (2009) Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur Heart J30: 718–730.
44.
National Institute on Drug Abuse (2001) Hallucinogens and Dissociative Drugs. National Institute on Drug Abuse research report series, NIH Publication, volume 01–4209; March, 2001.
45.
National Institute on Drug Abuse (2005) LSD NIDA Infofacts. National Institute on Drug Abuse, Rockville, MD; February, 2005.
46.
NuttDJKingLANicholsDE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci14: 577–585.
47.
OsmondHAlbaharyRCheekFSarettM (1967) Some problems in the use of LSD 25 in the treatment of alcoholism. In: AbramsonHA (ed) The use of LSD in psychotherapy and alcoholism. Indianapolis, IN: Bobbs-Merrill, 434–457.
48.
PahnkeWNKurlandAAUngerS. (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA212: 1856–1863.
49.
PerkinsKAConklinCALevineMD (2007) Cognitive-behavorial therapy for smoking cessation: A practical guidebook to the most effective treatments. New York: Routledge.
50.
PidermanKMSchneeklothTDPankratzVS. (2007) Spirituality in alcoholics during treatment. Am J Addict16: 232–237.
51.
PiedmontRL (2004) Spiritual transcendence as a predictor of psychosocial outcome from an outpatient substance abuse program. Psychol Addict Behav18: 213–222.
52.
PolingABrycelandJ (1979) Voluntary drug self-administration by nonhumans: A review. J Psychoactive Drugs11: 185–190.
53.
RossS (2012) Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am35: 357–374.
54.
SavageCMcCabeOL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry28: 808–814.
55.
ShiffmanSWestRJGilbertDG (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res6: 599–614.
56.
SmartRGStormTBakerEFW. (1966) A controlled study of lysergid in the treatment of alcoholism: The effects on drinking behavior. Quart J Stud Alcohol27: 469–485.
57.
SobellLCSobellMB (1992) Timeline follow-back: A technique for assessing self-reported alcohol consumption. In: LittenRAllenJ (eds) Measuring Alcohol Consumption. Rockville, MD: Humana Press: 207–224.
58.
SykesCMMarksDF (2001) Effectiveness of a cognitive behaviour therapy self-help programme for smokers in London, UK. Health Promot Int16: 255–260.
59.
TiffanySTDrobesDJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict86: 1467–1476.
60.
US Department of Health and Human Services (2014) The Health Consequences of Smoking: 50 Years of Progress: a Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
61.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci11: 642–651.
62.
WelschSKSmithSSWetterDW. (1999) Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp Clin Psychopharmacol7: 354–361.
63.
World Health Organization (2011) WHO report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco. Geneva, Switzerland: World Health Organization.
64.
ZernigGWallnerRGrohsU. (2008) A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction103: 2024–2031.
